Ginkgo Bioworks Holdings Long Term Debt

Ginkgo Bioworks Holdings (DNA) currently reports a long-term debt of $400M as of June 2026. That compares with $430M in the prior-year period — down 5.8% year over year. Use the charts on this page to explore Ginkgo Bioworks Holdings's long-term debt history and peer comparisons.

Ginkgo Bioworks Holdings's long-term debt decreased from $430M to $400M — a 5.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Ginkgo Bioworks Holdings reported $400M in long-term debt as of June 2026. That compares with $430M in the prior-year period — down 5.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $400M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Ginkgo Bioworks Holdings, and consider following DNA for alerts when major investors trade the stock.

Ginkgo Bioworks Holdings is classified in the Healthcare sector. On long-term debt, it currently shows $400M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DNA with unrelated industries.